GLP-1 (Glucagon-Like Peptide-1): Research, Uses, and Side Effects

GLP-1 drugs are now common in type 2 diabetes and obesity care. They are also widely discussed because they can change appetite, digestion, and body weight. That makes them useful, but it also means side effects matter.

• GLP-1 drugs mimic a natural hormone that helps control blood sugar, digestion, and appetite.
• They are approved for type 2 diabetes and, for some products, obesity treatment with diet and lifestyle changes.
• Common side effects include nausea, belly pain, diarrhea, constipation, and appetite changes.
• These medicines are not interchangeable. Each brand has its own approved uses, dose plan, and limits.

What GLP-1 Means

GLP-1 stands for glucagon-like peptide-1. In medicine, the term usually refers to GLP-1 receptor agonists. These drugs mimic a natural hormone made in the body. That hormone helps regulate blood sugar, food digestion, and appetite.

Research summaries in this bundle describe several key effects. GLP-1 drugs increase insulin production and release in a glucose-dependent way. They also decrease glucagon secretion, delay gastric emptying, and increase satiety. In simpler words, they help the body manage glucose while also making people feel full sooner.

That appetite effect is a major reason these medicines are used in weight management. A review from UVA Health notes that many people taking GLP-1 drugs eat fewer calories each day, often around 25% to 50% fewer calories daily. That is one reason body weight can change while on treatment.

Where GLP-1 Drugs Fit in Care

GLP-1 agonists are FDA-approved to manage type 2 diabetes and obesity when used with diet and lifestyle changes. They are not a replacement for insulin and should not be used to treat type 1 diabetes. They are also not one-size-fits-all medicines.

Common medications

The research bundle lists these GLP-1-related medicines: dulaglutide, exenatide, liraglutide, semaglutide, and tirzepatide. The names on the box matter because each drug has its own approved uses.

Examples from the sources include:

Semaglutide, sold as Ozempic, Wegovy, and Rybelsus.

Tirzepatide, sold as Mounjaro and Zepbound.

Liraglutide, sold as Victoza and Saxenda.

Dulaglutide, sold as Trulicity.

Exenatide, sold as Bydureon and Byetta.

The sources also note that semaglutide is the active ingredient in Ozempic and Wegovy, while Mounjaro and Zepbound contain tirzepatide. Because the active ingredient and approved use can differ, these products should not be used interchangeably.

Approved uses

For type 2 diabetes, several of these medicines are used with diet and exercise to improve glycemic control in adults. Trulicity and Victoza are also noted as options that reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes.

For weight loss, Saxenda, Wegovy, and Zepbound are described as medicines used to reduce excess body weight and help sustain reduced body weight. The key point is that the drug choice depends on the condition being treated.

How GLP-1 Drugs Work

The evidence in this bundle points to a shared mechanism across the class. GLP-1 drugs affect glycemic control and body weight through a small set of linked actions.

First, they help the pancreas release insulin in response to glucose. That glucose-dependent action is one reason these drugs are described as having a low overall risk of severe adverse effects in the source material.

Second, they reduce glucagon secretion. That matters because glucagon raises blood sugar. Lowering glucagon can help keep glucose under better control.

Third, they delay gastric emptying. Food stays in the stomach longer, which can change how full a person feels after eating.

Fourth, they increase satiety. This means people often feel full sooner and may naturally reduce intake.

These effects can be helpful, but they also explain many of the common side effects. If a medicine slows digestion and changes appetite, some stomach upset is expected.

Side Effects and Tolerability

The side effect profile is one of the most important parts of GLP-1 research. The bundle repeatedly emphasizes that the medicines can work well, but they can also cause digestive symptoms.

Common side effects listed in the sources include nausea, vomiting, stomach pain, diarrhea, constipation, and appetite changes. UVA Health also describes belly pain and diarrhea as common complaints. GoodRx similarly highlights nausea and vomiting, stomach pain, diarrhea, constipation, and appetite changes.

These effects are often tied to the way the medicines work. Because GLP-1 drugs affect digestion and appetite, stomach-related symptoms are especially common.

The Endocrinology Advisor review notes that GLP-1 agonists have a low overall risk of severe adverse effects. That does not mean side effects do not happen. It means serious problems are not the norm in the class summary provided here.

Why side effects matter

Side effects can affect whether someone stays on treatment. If nausea or bowel changes are strong enough, people may struggle to keep taking the drug. That is why side effect awareness is central to real-world use.

UVA Health frames the issue plainly: GLP-1 medicines may help with blood sugar and weight, but the side effects can “spoil the fun.” The practical lesson is that benefit and tolerability have to be weighed together.

Practical Details That Shape Treatment

These medicines are not all taken the same way. The sources note that most people take GLP-1 drugs as weekly or daily injections. The exact type, form, and dose depend on the person’s treatment plan.

That matters because dosing and schedule are part of tolerability. A medication that is approved for one schedule or one condition should not be assumed to work the same way as another.

The research also notes that there are no generic versions to date, which can affect access and cost. UVA Health recommends asking an insurer about coverage. In practice, that makes the product choice as much a logistics decision as a clinical one.

The class also includes both diabetes-focused and weight-focused products. That split is important. A medicine that helps with glucose control may not be approved for obesity, and a weight-loss product may have a different labeled use than a diabetes product with the same or related ingredient.

What Researchers and Clinicians Watch

GLP-1 research is not just about weight loss or blood sugar. It is also about matching the right medicine to the right person, and about knowing where the limits are.

One key issue is indication. The Endocrinology Advisor summary makes clear that GLP-1 agonists are approved for specific conditions, and should not be used interchangeably. That is a basic but important point for both researchers and clinicians.

Another issue is cardiovascular risk. The source notes that Trulicity and Victoza are indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes. That makes the class relevant not only to metabolism, but also to broader outcomes in diabetes care.

A third issue is adherence over time. If a person gets the expected metabolic effect but cannot tolerate the medicine, the real-world value drops. Digestive side effects, dose schedules, and coverage all shape use.

Finally, the research bundle reflects the popularity of GLP-1s beyond prescription use. Some of the linked material is commercial and consumer-facing, which shows how much public interest has grown. But the strongest claims in this set remain clinical: blood sugar control, appetite effects, approved uses, and side effects.

FAQ

What is GLP-1?

GLP-1 stands for glucagon-like peptide-1. In medicine, it usually refers to a group of GLP-1 receptor agonist drugs that mimic a natural hormone involved in blood sugar control, digestion, and appetite.

What do GLP-1 drugs do?

They increase insulin release in a glucose-dependent way, decrease glucagon secretion, delay gastric emptying, and increase satiety. These combined effects help with glycemic control and can reduce appetite.

What are the most common side effects?

The sources list nausea, vomiting, stomach pain, diarrhea, constipation, belly pain, and appetite changes. These are the main side effects people are told to watch for.

Which GLP-1 medicines are mentioned in the research?

The bundle names dulaglutide, exenatide, liraglutide, semaglutide, and tirzepatide. Brand names listed include Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, Bydureon, and Byetta.

Are GLP-1 drugs only for weight loss?

No. The research says they are FDA-approved for type 2 diabetes and obesity, depending on the product, and some are also used to reduce major adverse cardiovascular events in adults with type 2 diabetes.